Clinical Trial Update: A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and preliminary efficacy of KITE-363 in relapsed/refractory autoimmune neurologic diseases is currently recruiting, includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy
• Multiple Sclerosis
• Myasthenia Gravis

Drugs mentioned

• KITE-363

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis | Phase 1 | Status: RECRUITING